CHRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Coherus Oncology Inc (CHRS) does not present a strong buy opportunity for a beginner, long-term investor at this time. Despite a bullish analyst rating and significant upside potential, the technical indicators and lack of recent positive catalysts suggest a cautious approach. The stock's bearish moving averages, lack of recent news, and neutral insider and hedge fund activity do not support immediate action. Additionally, Intellectia Proprietary Trading Signals show no buy signals today.
The MACD is positive and expanding, suggesting mild bullish momentum. However, the RSI is neutral at 59.544, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels are Pivot: 1.436, R1: 1.528, S1: 1.344, R2: 1.584, S2: 1.288. The stock is trading near its resistance level, which may limit immediate upside potential.
Guggenheim's bullish rating with a $12 price target and potential upside to $18, driven by the company's transformation into a pure-play immuno-oncology firm and promising CCR8 mechanism.
Bearish moving averages, lack of recent news or significant insider/hedge fund activity, and a high chance of negative price movement in the short term (-0.61% in the next day, -5.56% in the next month).
No financial data available for analysis.
Guggenheim initiated coverage with a Buy rating and a $12 price target, citing a favorable risk/reward profile and significant upside potential.
